ASX Release 20 November 2026 ASX code: PIQ 2026 Annual General Meeting Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to present the Chair’s Address and Company Presentation to be presented at the...
AGM Chair and CEO Address and Presentation
Filed with ASX · · 13 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. presented the Chair’s Address and CEO’s presentation at its Annual General Meeting, outlining the company's transition to a commercially-focused diagnostics business. The CEO highlighted the launch of three diagnostic tests and the strategic partnership with Healius to enhance distribution and market access. The company aims to build clinician adoption and revenue while managing funding and operational efficiency.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Proteomics International Laboratories Ltd. on 6ix
In the deck
Story so far
Earlier from Proteomics International Laboratories
- Change of Director's Interest Notice
- Security Purchase Plan Offer Booklet Update
- Amended Notice of Annual General Meeting/Proxy Form
- Investor Webinar Presentation
- Security Purchase Plan Offer Booklet
Later from Proteomics International Laboratories
All Proteomics International Laboratories news releasesFollow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories